Non-Hodgkin lymphoma

Last updated: February 23, 2023

Non-Hodgkin lymphoma

BIIC

BIIC

Thymus histology
Spleen histology
Lymph node histology
Immunodeficiencies: T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Combined T-cell and B-cell disorders: Pathology review
Immunodeficiencies: Phagocyte and complement dysfunction: Pathology review
Blood histology
Blood components
Blood groups and transfusions
Platelet plug formation (primary hemostasis)
Coagulation (secondary hemostasis)
Role of Vitamin K in coagulation
Clot retraction and fibrinolysis
von Hippel-Lindau disease
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Pyruvate kinase deficiency
Hereditary spherocytosis
Beta-thalassemia
Alpha-thalassemia
Iron deficiency anemia
Anemia of chronic disease
Sickle cell disease (NORD)
Erythropoietin
Hemophilia
Vitamin K deficiency
Von Willebrand disease
Sideroblastic anemia
Autoimmune hemolytic anemia
Paroxysmal nocturnal hemoglobinuria
Aplastic anemia
Fanconi anemia
Folate (Vitamin B9) deficiency
Vitamin B12 deficiency
Megaloblastic anemia
Diamond-Blackfan anemia
Lead poisoning
Bernard-Soulier syndrome
Hemolytic-uremic syndrome
Thrombotic thrombocytopenic purpura
Immune thrombocytopenia
Glanzmann's thrombasthenia
Disseminated intravascular coagulation
Heparin-induced thrombocytopenia
Antithrombin III deficiency
Protein C deficiency
Antiphospholipid syndrome
Factor V Leiden
Protein S deficiency
Polycythemia vera (NORD)
Mixed platelet and coagulation disorders: Pathology review
Coagulation disorders: Pathology review
Macrocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Platelet disorders: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Myeloproliferative disorders: Pathology review
Anticoagulants: Heparin
Anticoagulants: Warfarin
Thrombolytics
Hematopoietic medications
Protein synthesis inhibitors: Tetracyclines
DNA synthesis inhibitors: Fluoroquinolones
Cell wall synthesis inhibitors: Cephalosporins
Cell wall synthesis inhibitors: Penicillins
Protein synthesis inhibitors: Aminoglycosides
Yellow fever virus
Dengue virus
Ebola virus
Hantavirus
Salmonella typhi (typhoid fever)
Yersinia pestis (Plague)
Borrelia burgdorferi (Lyme disease)
Rickettsia rickettsii (Rocky Mountain spotted fever) and other Rickettsia species
Coxiella burnetii (Q fever)
Ehrlichia and Anaplasma
Hodgkin lymphoma
Non-Hodgkin lymphoma
Chronic leukemia
Acute leukemia
Myelodysplastic syndromes
Myelofibrosis (NORD)
Essential thrombocythemia (NORD)
Multiple myeloma
Waldenstrom macroglobulinemia
Leukemias: Pathology review
Lymphomas: Pathology review
Plasma cell disorders: Pathology review
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
HIV and AIDS: Pathology review
HIV (AIDS)
Integrase and entry inhibitors
Protease inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)

Transcript

Watch video only

Content Reviewers

The term non-Hodgkin lymphoma, sometimes called NHL, can be broken down. Lymph- refers to lymphocytes and oma- refers to a tumor.

“Non-Hodgkin” refers to the absence of a key cell that’s seen in Hodgkin lymphoma, the Reed-Sternberg cell.

So, non-Hodgkin lymphoma is a tumor derived from lymphocytes - specifically B-cells and T-cells, which mainly live in the lymph nodes and move through the blood and lymphatic system.

Now, B-cell development begins in the bone marrow, which is a primary lymphoid organ. That’s where young precursor B-cells mature into naive B-cells.

The naive B cells then leave the bone marrow and circulate in the blood and eventually settle down in lymph nodes.

Humans have hundreds of lymph nodes, scattered throughout the body, and they’re considered secondary lymphoid organs.

Each lymph node has B-cells which group together in follicles in the cortex or outer part of the lymph node, along with T-cells in the paracortex just below the cortex.

B-cells differentiate into plasma cells, which are found in the medulla or center of the lymph node.

Plasma cells release antibodies or immunoglobulins.

Antibodies bind to pathogens like viruses and bacteria, to help destroy or remove them.

Various immune cells, including B-cells have surface proteins or markers that are called CD, short for cluster of differentiation, along with a number - like CD19 or CD21.

In fact, the combination of surface proteins that are on an immune cell works a bit like an ID card.

Now, a B cell is activated when it encounters an antigen that binds just perfectly to its surface immunoglobulin.

Some of these activated B-cells mature directly into plasma cells and produce IgM antibodies.

Other activated B-cells go to the center of a primary follicle in the lymph node and they differentiate into B-cells called centroblasts and start to proliferate or divide.

These proliferating centroblasts form a germinal center, located in the center of the follicle of the lymph node.

These centroblasts have a rearrangement of their immunoglobulin genes, and some of them undergo a class switch where they change from producing IgM antibodies to producing IgG or IgA antibodies.

Within the germinal center, centroblasts mature into centrocytes; and the centrocytes that make antibody with high affinity for the antigen, differentiate into either plasma cells which go to the medulla or memory B-cells which circulate in the blood and reside in lymph nodes, spleen, and mucosa-associated lymphoid tissue, also called MALT.

Now, T-cell development starts in the thymus from precursors that arise in the bone marrow.

In the thymus, these precursor T-cells mature and express either CD4 on helper T-cells or CD8 on cytotoxic T-cells sometimes known as suppressor T cells.

Mature T-cells circulate in the blood and are found in the paracortex of the lymph nodes.

In non Hodgkin lymphoma, there is usually a genetic mutation in a lymphocyte - either a B cell or a T cell. When something like that happens, cells are supposed to undergo apoptosis - or programmed cell death, but instead the lymphocyte starts to divide uncontrollably - becoming a neoplastic cell.

Usually, lymphomas develop in lymph nodes and they’re called nodal lymphomas.

Lymphomas can happen anywhere in the body, though, and when they develop in other tissues or organs - like the stomach or skin - they’re called extranodal lymphomas.

Lymphoma cells can also get into the blood and can spread to other parts of the body.

If lymphoma cells get into the gastrointestinal tract they can grow and cause bowel obstruction. If they go to the bone marrow, they can crowd out normal bone marrow progenitor cells and decrease the number of healthy red blood cells, white blood cells and platelets. If they go to the spinal cord they can cause spinal cord compression.

Now, the two main groups of Non-Hodgkin lymphomas are B cell and T cell lymphomas.

B cell lymphomas are more common and the neoplastic B cells usually express CD20 on their surface.

And there are various types of B cell lymphomas and an important feature is how quickly each one grows- they can be indolent or slow to grow, aggressive, or highly aggressive.

The first type of B cell lymphoma is a diffuse large B cell lymphoma, this type is the most common and it’s an aggressive lymphoma.

A second type of B cell lymphoma is a follicular lymphoma, and it’s an indolent lymphoma.

One known mechanism for how a follicular lymphoma develops, is a chromosomal translocation between chromosome 14 and chromosome 18.

In the translocation, the two chromosomes swap large pieces of chromosome with each other. As a result the BCL2 gene from chromosome 18 is placed after the immunoglobulin heavy chain promoter on chromosome 14, and that results in overexpression of bcl-2.

Bcl-2 normally blocks cell death, or apoptosis, so overexpression of the bcl-2 gene prevents the cell from dying.

A third type of B cell lymphoma is Burkitt lymphoma, and it’s a highly aggressive lymphoma.

Burkitt lymphoma can also result from a chromosomal translocation. In this case, the Myc gene is translocated from chromosome 8 where it ends up adjacent to IgH promoter on chromosome 14 and again that upregulates its expression.

Key Takeaways

Non-Hodgkin lymphomas are a group of blood cancers that include any kind of lymphoma except Hodgkin's lymphomas. Hodgkin's lymphoma is characterized by the presence of a specific type of cell called a Reed-Sternberg cell. A lymphoma that lacks this specific cell, is a non-Hodgkin lymphoma. Non-Hodgkin lymphomas can originate from B cells or T cells, though they most commonly arise from B cells.

Symptoms of non-Hodgkin lymphomas include enlarged lymph nodes, fever, night sweats, weight loss, and fatigue. Other symptoms may include bone pain, chest pain, or itchiness. Some forms are slow growing while others are fast-growing. Treatment usually involves chemotherapy and radiation therapy, depending on the lymphoma subtype, aggressivity, and how far it has spread.

Sources

  1. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  2. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  3. "Yen & Jaffe's Reproductive Endocrinology" Saunders W.B. (2018)
  4. "Bates' Guide to Physical Examination and History Taking" LWW (2016)
  5. "Robbins Basic Pathology" Elsevier (2017)
  6. "Familial predisposition and genetic risk factors for lymphoma" Blood (2015)
  7. "HIV-related lymphoma" HIV Therapy (2010)
  8. "Non-Hodgkin Lymphoma" Cancer in Adolescents and Young Adults